Update information
January 2014: Implementation section was updated to clarify that fingolimod is recommended as an option for treating highly active relapsing–remitting multiple sclerosis.
ISBN: 978-1-4731-6710-0
January 2014: Implementation section was updated to clarify that fingolimod is recommended as an option for treating highly active relapsing–remitting multiple sclerosis.
ISBN: 978-1-4731-6710-0